HPHao Pan

Hao Pan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hao Pan has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells

    by Shiyu Xiao, Michihiro Kobayashi, Yunpeng Bai, Wenjie Cai, Sergio Barajas, Mohammed Abdullahel Amin, Sasidhar Vemula, Chonghua Yao, Yuxia Yang, Christopher Borchers, et al.

    Acute myeloid leukemia (AML) is an aggressive hematological malignancy that is sustained by leukemia-initiating cells (LICs). Although protein tyrosine phosphatase 4A2 (PTP4A2), also known as phosphatase of regenerating liver 2 (PRL2), is highly expressed in AML, the mechanisms by which PTP4A2 promotes leukemogenesis are largely unexplored. In this study, we demonstrate that PTP4A2 promotes AML by inhibiting the p53 tumor suppressor pathway in LICs. Using KMT2A-MLLT3–driven AML as a model, we found that PTP4A2 deficiency activates p53 and induces LIC apoptosis and senescence, thereby extending the survival of recipient mice repopulated with Ptp4a2−/− LICs. Mechanistically, PTP4A2 directly interacts with p53 and dephosphorylates it at serine 392, decreasing p53 stability and activity to enhance LIC proliferation and survival. Collectively, our findings identify p53 as a potential PTP4A2 substrate in leukemia cells and uncover a novel mechanism by which PTP4A2 enhances LIC maintenance.


  • Open Access

    A bivalent lysine-acetylated small-molecule binding site in MYC

    by Dikshat G. Gupta, Mihai I. Truica, Adam W.T. Steffeck, J. Brandon Parker, Daniel H. Ryan, Hao Pan, William Yang, Xinyan Lu, Kenji Unno, Songhua Quan, et al.

    MYC is an important, yet challenging target in oncology as it lacks traditional “druggable” pockets. Here we show that two regions of the MYC protein, the basic-Helix-Loop-Helix (bHLH) domain, and an extended MYC Box II (eMBII) come together to form a bivalent, high-affinity small-molecule MYC inhibitor (MYCi) binding site. CRISPR-tiling mutagenesis identified mutations in the vicinity of emBII and in bHLH regions that together confer MYCi resistance. Importantly, acetylation of lysine K148 in eMBII which is essential for MYC oncogenicity in vivo increased the predicted order of this region and enhanced MYCi binding affinity. Furthermore, MYCi selectively modulated the expression of the same genes regulated by lysine-acetylated MYC in cancer cells. These studies provide a rationale for the selective targeting of acetylated, oncogenic MYC with small molecules.

  • Development of DOT1L-Targeted Protein Degraders for Treating MLL-r Leukemia

    by Songhua Quan, Kenji Unno, Dikshat G. Gupta, William Yang, Qianyu Guo, Mary F. Dufficy, Megan M. Kerber, Ala A. Elmashae, Harrison Pan, Joshua L. Zhu, et al.

    DOT1L is aberrantly recruited in MLL-r leukemias and serves as a critical oncogenic driver. Substantial previous work has developed catalytic inhibitors like pinometostat, which showed limited clinical efficacy. Recent work has defined nonenzymatic functions of DOT1L in promoting leukemia progression. Because these functions cannot be blocked by enzymatic inhibitors, we developed novel DOT1L-targeting PROTACs (Proteolysis-Targeting Chimeras ) to degrade the protein and thereby block all of its functions. We describe PROTACs DOT1L705 and DOT1L808 as potent and highly selective DOT1L degraders with DC50 values of 0.33 μM and 5 nM, respectively. The effect of DOT1L705 on cell viability is highly dependent on the MLL-r status of leukemia cell lines, and it retains activity against menin inhibitor-resistant cells. In vivo studies with DOT1L808 showed its ability to achieve complete tumor regression in an orthotopic leukemia model without overt toxicity. These results establish protein degradation as a promising therapeutic strategy for MLL-rearranged leukemias.


  • Open Access

    Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors

    by William Yang, Qianyu Guo, Songhua Quan, Zachary R Chalmers, J Brandon Parker, Mihai Truica, Mary F Dufficy, Megan M Kerber, Karthik Vasan, Dikshat G Gupta, et al.

    MYC is a key driver in many aggressive and therapy-resistant cancers. We have developed and characterized a small-molecule MYC inhibitor named MYCi975. To uncover combination strategies for MYC inhibitors, we conducted a genome-wide CRISPR screen using MYCi975. This screen revealed a notable synthetic lethality when MYC inhibition was paired with disruption of mitochondrial complex I components, but not other complexes. Mechanistically, MYC inhibition reduced oxidative phosphorylation and glycolysis, triggering a compensatory up-regulation of complex I genes. Consequently, genetic or pharmacological targeting of complex I sensitized tumors to MYCi975 treatment, leading to increased purine catabolism and infiltration of CD8 + T cells and macrophages into tumors. Additionally, a wide range of tumor cells with lower complex I expression showed increased MYC dependency. These results indicate that metabolic adaptation to MYC inhibition exposes a targetable weakness at complex I and provide a rational strategy for combination therapy with emerging MYC inhibitors.


  • Open Access

    A method for low-coverage single-gamete sequence analysis demonstrates adherence to Mendel’s first law across a large sample of human sperm

    by Sara A Carioscia, Kathryn J Weaver, Andrew N Bortvin, Hao Pan, Daniel Ariad, Avery Davis Bell, Rajiv C McCoy

    Recently published single-cell sequencing data from individual human sperm (n=41,189; 969–3377 cells from each of 25 donors) offer an opportunity to investigate questions of inheritance with improved statistical power, but require new methods tailored to these extremely low-coverage data (∼0.01× per cell). To this end, we developed a method, named rhapsodi, that leverages sparse gamete genotype data to phase the diploid genomes of the donor individuals, impute missing gamete genotypes, and discover meiotic recombination breakpoints, benchmarking its performance across a wide range of study designs. We then applied rhapsodi to the sperm sequencing data to investigate adherence to Mendel’s Law of Segregation, which states that the offspring of a diploid, heterozygous parent will inherit either allele with equal probability. While the vast majority of loci adhere to this rule, research in model and non-model organisms has uncovered numerous exceptions whereby ‘selfish’ alleles are disproportionately transmitted to the next generation. Evidence of such ‘transmission distortion’ (TD) in humans remains equivocal in part because scans of human pedigrees have been under-powered to detect small effects. After applying rhapsodi to the sperm data and scanning for evidence of TD, our results exhibited close concordance with binomial expectations under balanced transmission. Together, our work demonstrates that rhapsodi can facilitate novel uses of inferred genotype data and meiotic recombination events, while offering a powerful quantitative framework for testing for TD in other cohorts and study systems.


  • Open Access

    Erratum: Lattice constants from semilocal density functionals with zero-point phonon correction [Phys. Rev. B85, 014111 (2012)]

    by Pan Hao, Yuan Fang, Jianwei Sun, Gábor I. Csonka, Pier H. T. Philipsen, John P. Perdew

    DOI: http://dx.doi.org/10.1103/PhysRevB.85.099903 ©2012 American Physical Society